News and Announcements
Proteomics Secures First Commercialisation Deal for PromarkerD
- Published August 18, 2016 2:45PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
18th August 2016, ASX Announcement
Life sciences company Proteomics International Laboratories (ASX: PIQ) (PILL) has signed an exclusive license for its PromarkerD assay for the diagnosis of diabetic kidney disease in the Dominican Republic in Central America.
Highlights:
- Diabetic kidney disease test to be commercialised in the Dominican Republic in a deal worth in excess of USD 1.5 million.
- The agreement marks the first international licensing deal for the PromarkerD assay.
- Manufacturing will occur in US Territory of Puerto Rico and the deal paves the way for other markets including the United States, China and Japan.
The licence granted to Omics Global Solution (Omics) for the Dominican Republic for the PromarkerD assay will provide significant economic benefit to PILL. Although the Dominican Republic has only 10.6 million people, the net present value of financial terms in excess of USD 1.5M for the first nine years of the agreement.
To view the full announcement, please click on the button below.